1-12 of 12
Sarah Norek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

Barry Paul, Myra Robinson, James Symanowski, David M Foureau, Sarah Norek, Manisha Bhutani, Christopher Ferreri, Ami P Ndiaye, Jordan Robinson, Shebli Atrash, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, April Smith, Jessica Duda, Lance Cooper, Amani Kitali, Peter M. Voorhees
Journal: Blood
Blood (2024) 144 (Supplement 1): 7027.
https://doi.org/10.1182/blood-2024-208830
Published: 2024
Journal Articles

Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

Shebli Atrash, James Symanowski, Sarah Norek, Monica Plott, Cecilia Flynn, Kelly Bumgarner, Darynne Rhinehardt, Xhevahire Begic, Robin Cox, Barry Paul, Cindy Varga, Reed Friend, Christopher Ferreri, Manisha Bhutani, Mauricio Pineda-Roman, Peter M. Voorhees
Journal: Blood
Blood (2024) 144 (Supplement 1): 4751.
https://doi.org/10.1182/blood-2024-205957
Published: 2024
Journal Articles

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Barry Paul, Mauricio Pineda-Roman, David Foureau, Cindy Varga, Reed Friend, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B Anderson, James Symanowski, Peter M. Voorhees, Saad Z Usmani
Journal: Blood
Blood (2023) 142 (Supplement 1): 3380.
https://doi.org/10.1182/blood-2023-174972
Published: 2023
Journal Articles

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma

Steven I. Park, Lakshmi Nayak, Danielle Boselli, Raphael E Steiner, Ashley L Sumrall, Nazanin K Majd, Xhevahire Begic, Sarah Norek, Christopher Dittus
Journal: Blood
Blood (2023) 142 (Supplement 1): 1723.
https://doi.org/10.1182/blood-2023-179526
Published: 2023
Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Nicole Watts, Barry Paul, Saurabh Chhabra, Neha Korde, Xhevahire Begic, David M Foureau, David J. Chung, Mauricio Pineda-Roman, Brinda Koya, Cindy Varga, Jing Ai, Natonya Daniels, Sarah Norek, Sara A Sutton, Michelle B Anderson, Ashley N Jewell, Paul W Eldridge, Donna Acampora, James T Symanowski, Luciano J. Costa, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 4393–4395.
https://doi.org/10.1182/blood-2022-160071
Published: 2022
Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 4440–4441.
https://doi.org/10.1182/blood-2022-160204
Published: 2022
Journal Articles

Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Aleksander L. Chojecki, Jai N. Patel, David M Foureau, James Symanowski, Xhevahire Begic, Michael Davis, Nury M Steuerwald, Sarah Norek, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Brittany Knick Ragon, Thomas G. Knight, Jing Ai, Michael R. Grunwald, Nilanjan Ghosh, Lawrence J Druhan, Belinda R. Avalos, Edward A. Copelan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10534–10536.
https://doi.org/10.1182/blood-2022-160214
Published: 2022
Journal Articles

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Manisha Bhutani, Myra Robinson, Shebli Atrash, David M Foureau, Katherine Rigby, Reed Friend, Barry Paul, James T Symanowski, Lawrence J Druhan, Sarah Norek, Mallory Tucker, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2739.
https://doi.org/10.1182/blood-2021-148508
Published: 2021
Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-138485
Published: 2020
Journal Articles

A Phase 2 Trial of Daratumumab and Pembrolizumab in Refractory Multiple Myeloma

Barry Paul, MDMS, James Symanowski, PhD, Paul Osipoff, Sarah Norek, BSN, RN, Ami P Ndiaye, NP, Jordan Robinson, Shebli Atrash, MD, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 2.
https://doi.org/10.1182/blood-2020-141623
Published: 2020
Journal Articles

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Shebli Atrash, MD, Myra Robinson, MSPH, Barry Paul, MDMS, Sarah Norek, BSN, RN, David M. Foureau, PhD, Carrie Ann Syfert, BSN, RN, Ami P Ndiaye, NP, James T Symanowski, PhD, Jordan Robinson, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-141562
Published: 2020
Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 5570.
https://doi.org/10.1182/blood-2019-130290
Published: 2019